Last reviewed · How we verify

Oxytropium Bromide (OXITROPIUM)

Phase 3 active Small molecule ✓ Verified May 2026

Oxytropium Bromide (generic name: OXITROPIUM) is a oxitropium drug. It is currently in Phase 3 development for Chronic obstructive lung disease.

Oxytropium works by blocking the action of acetylcholine, a neurotransmitter that causes airway muscles to contract.

Oxytropium bromide is a small molecule medication used to treat conditions such as chronic obstructive pulmonary disease (COPD) and critical illness. It is administered via a metered dose inhaler, powder inhalation capsules, or other formulations like Ventilat, Tiotropium, and Tersigan.

Likelihood of approval
55.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • CNS / neurology attrition -3.0pp
    CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameOXITROPIUM
Drug classoxitropium
ModalitySmall molecule
Therapeutic areaNeuroscience
PhasePhase 3

Mechanism of action

Imagine your airways are like a narrow tube. When you breathe, the muscles around the tube relax, allowing air to flow in and out. Oxytropium helps keep these muscles relaxed, making it easier to breathe by blocking the signal that tells them to contract.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oxytropium Bromide

What is Oxytropium Bromide?

Oxytropium Bromide (OXITROPIUM) is a oxitropium drug, indicated for Chronic obstructive lung disease.

How does Oxytropium Bromide work?

Oxytropium works by blocking the action of acetylcholine, a neurotransmitter that causes airway muscles to contract.

What is Oxytropium Bromide used for?

Oxytropium Bromide is indicated for Chronic obstructive lung disease.

What is the generic name of Oxytropium Bromide?

OXITROPIUM is the generic (nonproprietary) name of Oxytropium Bromide.

What drug class is Oxytropium Bromide in?

Oxytropium Bromide belongs to the oxitropium class. See all oxitropium drugs at /class/oxitropium.

What development phase is Oxytropium Bromide in?

Oxytropium Bromide is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing